Sanità internazionale 8 Giugno 2016 13:27

Towards an “universal” vaccine against the cancer

A team of German researchers has used some nanoparticles containing RNA of tumour cells, capable to stimulate an immunity answer that tackle the tumour cells themselves, by achieving encouraging results. This progress can be a starting point for “a new class of universal applicable vaccines for the immunotherapy against the cancer”. This is the conclusion […]

A team of German researchers has used some nanoparticles containing RNA of tumour cells, capable to stimulate an immunity answer that tackle the tumour cells themselves, by achieving encouraging results. This progress can be a starting point for “a new class of universal applicable vaccines for the immunotherapy against the cancer”. This is the conclusion of a German scientific article published the 2 June on the review Nature. This is a turning point verified only on a small number of patients and for this reason not yet achieved.  But the research is considered very promising by the experts. The idea is simple: stimulating the immunity system of a person affected by cancer to induce him to recognise his own tumour cells. This is easier said than done, but the cancer, different from a virus that is rapidly recognised by the body, is made up of some cells which are very similar to normal cells: for this reason the immunity system doesn’t attack them spontaneously. Moreover, the development of the cancer is not accompanied by an inflammation (and other biochemical warning signals) as in the case of a microbial invasion. This is the reason why a person can live with the cancer for many years without knowing it.

GLI ARTICOLI PIU’ LETTI
Advocacy e Associazioni

Porpora trombotica trombocitopenica. ANPTT Onlus celebra la III Giornata nazionale

Evento “WeHealth” promosso in partnership con Sanofi e in collaborazione con Sics Editore per alzare l’attenzione sulla porpora trombotica trombocitopenica (TTP) e i bisogni ancora i...
Salute

Tumori: boom di casi nei paesi occidentali. Cinieri (Aiom): “Prevenzione attiva per ridurre carico della malattia”

Nel 2024 negli USA, per la prima volta nella storia, si supera la soglia di 2 milioni di casi di tumore. Una crescita importante, comune a tutti i Paesi occidentali. Per Saverio Cinieri, presidente di...
Salute

Tumore del polmone non a piccole cellule di stadio precoce e avanzato: lo stato dell’arte di nivolumab

Sono stati presentati al recente Congresso ASCO gli aggiornamenti degli studi relativi all’impiego di nivolumab nel tumore del polmone non a piccole cellule di stadio precoce e avanzato. Il quad...
Advocacy e Associazioni

Cirrosi epatica, i pazienti chiedono meno burocrazia e maggior accesso al teleconsulto

Nella nuova puntata di The Patient Voice, Ivan Gardini (EpaC Ets), Ilenia Malavasi (Affari Sociali) e Francesca Ponziani (Pol. Gemelli)